Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Data ReadoutpositiveCARVYKTIPositive

AI Analysis

Summary

Johnson & Johnson announced five-year data for CARVYKTI showing 50% of patients achieved treatment-free remissions in early line relapsed/refractory multiple myeloma. The results support earlier intervention with the CAR-T therapy for improved long-term outcomes.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Single infusion delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Importance:7/10

Sentiment:

0.85

multiple myelomaCAR-Tclinical dataremissiontreatment-free

Related Companies

$JNJ

Read the original article

Published by PR Newswire Biotech on September 25, 2026 11:00 AM

Read Original